Video

Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

Transcript:

Sara Hurvitz, MD: Back to what we’re using in clinical practice. Virginia, take us through our standard of care, based on NCCN [National Comprehensive Cancer Network] Guidelines. What should we be doing in the adjuvant setting?

Virginia G. Kaklamani, MD, DSc: Assuming a patient hasn’t received neoadjuvant therapy and they’re coming in after surgery, the NCCN Guidelines are relatively vague as to whether to give trastuzumab-based chemotherapy in small tumors. But they say we should consider it for T1a and T1b disease. This is based on data coming from the Netherlands looking at a prospective cohort of patients, [where the] T1b patients receiving trastuzumab have better outcomes. There was a suggestion that T1a patients also did.

I consider that when I talk to my patients. I recommend it for my patients with T1b disease, and I discuss it with my patients with T1a. For T1c, adjuvant trastuzumab-based chemotherapy is considered standard. Most of us will use the APT [adjuvant paclitaxel-trastuzumab] regimen with weekly paclitaxel and a year of trastuzumab. NCCN guidelines say we should then consider pertuzumab in N1 tumors, which is important. Also, in HER [human epidermal growth factor receptor 2]–positive higher-risk tumors, consider neratinib as well for extended endocrine therapy.

Sara Hurvitz, MD: That sounds good. That’s very clear. Melinda, let’s dive a little deeper into the use of pertuzumab and the data supporting the use of pertuzumab.

Melinda L. Telli, MD: This was an interesting story in breast cancer because the drug got approved about 10 years ago in the preoperative setting. It was an accelerated approval based on phase 2 trials showing increase in the rate of pCR [pathologic complete response] with the addition of pertuzumab to chemotherapy and trastuzumab. A few years later, we finally saw the approval of pertuzumab in the adjuvant setting. Initially it was somewhat unclear which patients were going to benefit.

APHINITY was a large, very standard adjuvant study. It’s the kind of study we don’t see too much anymore. Patients had surgery up front. [There were] nearly 5000 patients, and they had the choice of an anthracycline-taxane-based chemotherapy backbone with trastuzumab or the docetaxel-carboplatin regimen with trastuzumab. They were randomized to receive pertuzumab or not. When the study was first reported, there was a small benefit in invasive disease-free survival of about 1.6%. It has been subsequently updated at the 6-year time point and most recently at the 8-year time point, showing that there’s just under a 3% benefit in the overall population. It approaches 5% in the lymph node–positive [population]. At this point, there isn’t any impact on overall survival. It’s an invasive disease-free survival benefit and supports the use in node-positive disease.

Transcript edited for clarity.

Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
5 KOLs are featured in this series.